| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 30, 2012Multicenter Experience Demonstrates Surgical Approach, with Recent CE Mark, is a Feasible Alternative for Transcatheter Aortic Valve Implantation
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 30, 2012-- Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve® System delivered...
-
Jan 30, 2012Multicenter Experience Demonstrates Surgical Approach, with Recent CE Mark, is a Feasible Alternative for Transcatheter Aortic Valve Implantation
MINNEAPOLIS, Jan 30, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve(R) System delivered...
-
Jan 27, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 27, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC – a company...
-
Jan 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized,...
-
Jan 24, 2012CoreValve U.S. Trial to Continue Enrolling Patients in High Risk Study, and Will Maintain Therapy Access to Extreme Risk Patients via Continued Access Phase of Trial
MINNEAPOLIS, Jan 24, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The...
-
Jan 23, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 23, 2012-- Medtronic, Inc. (NYSE:MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS...
-
Jan 17, 2012Enhanced Medical Device to Repair Abdominal Aortic Aneurysms Without Open Surgery Expands Physicians’ Options for Treating ‘Silent Killer’
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 17, 2012-- Medtronic Inc. (NYSE: MDT) today announced the CE (Conformité Européenne) mark and international launch of the Endurant®II AAA Stent Graft System,...
-
Jan 17, 2012Enhanced Medical Device to Repair Abdominal Aortic Aneurysms Without Open Surgery Expands Physicians' Options for Treating 'Silent Killer'
MINNEAPOLIS, Jan 17, 2012 (BUSINESS WIRE) --Medtronic Inc. (NYSE: MDT) today announced the CE (Conformité Européenne) mark and international launch of the Endurant(R) II AAA Stent Graft System,...
-
Jan 4, 2012mySentry Allows Caregivers to See Real-Time Insulin Pump Information and Glucose Trends from Another Room
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 4, 2012-- Today, Medtronic, Inc. (NYSE:MDT) announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind...
-
Dec 23, 2011
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 23, 2011-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the 30th Annual JP Morgan...
-
Dec 20, 2011
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 22, 2011-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Goldman Sachs Healthcare...
-
Dec 12, 2011
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 12, 2011-- Medtronic, Inc. (NYSE: MDT) today announced that the Company has reached a settlement agreement with the United States Department of Justice (DOJ)...
-
Dec 10, 2011
MINNEAPOLIS, Nov 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the second quarter of its fiscal year 2012 on Tuesday, November 22,...
-
Dec 9, 2011Neurostimulator with Innovative Motion Sensor Technology Was Recently Approved by the FDA for the Management of Chronic Pain
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 9, 2011-- Clinical trial data presented at the 15th Annual Meeting of the North American Neuromodulation Society demonstrate the AdaptiveStim™ with...
-
Dec 8, 2011
MINNEAPOLIS, Dec 08, 2011 (BUSINESS WIRE) -- The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.2425 per share of the Company's common stock. The dividend is...
-
Dec 7, 2011Medtronic CRT-D Devices Demonstrate Survival Benefits for Mildly Symptomatic Heart Failure Patients in Two Pivotal Clinical Trials
MINNEAPOLIS--(BUSINESS WIRE)--Dec. 7, 2011-- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration’s (FDA) Circulatory Systems Devices Advisory Panel determined...
-
Nov 21, 2011
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 21, 2011-- Medtronic, Inc. (NYSE: MDT), the world’s leading medical technology company, today announced it will participate in the Piper Jaffray Healthcare...
-
Nov 20, 2011Revenue of $4.1 Billion Grew 3% on a Constant Currency Basis, 6% as Reported
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 22, 2011-- Medtronic, Inc. (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2012, which ended October 28, 2011. The company...
-
Nov 20, 2011iPro®2 Simplifies Professional CGM for Improved Diabetes Therapy Management
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 22, 2011-- Medtronic, Inc. (NYSE:MDT) today announced the Food and Drug Administration (FDA) approval of iPro®2, a next generation Professional continuous...
-
Nov 17, 2011
MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Nov. 17, 2011-- Medtronic, Inc. (NYSE:MDT) and Bain Capital, a leading global private investment firm, today announced they have entered into a definitive...
-
Nov 17, 2011Neurostimulator Uses Innovative Motion Sensor Technology to Provide Patient Comfort and Convenience
MINNEAPOLIS--(BUSINESS WIRE)--Nov. 17, 2011-- Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food & Drug Administration (FDA) approval of its AdaptiveStim™ with RestoreSensor™...
-
Nov 10, 2011Campaign Empowers People With a Slow Heartbeat to Learn About Treatment Options and How to Have an Informed Discussion With Their Doctor
Famed dancer, actress, and director Debbie Allen has teamed up with Medtronic, Inc. (NYSE: MDT) today to kick off "Join the Pace Makers," a national campaign designed to empower people with a...
-
Nov 9, 2011
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today reported results of an retrospective study available online and in an upcoming print edition of the Journal of Spinal...
-
Nov 9, 2011Study Will Evaluate Accuracy of Latest Innovation to Help People with Diabetes Improve Glucose Control
MINNEAPOLIS, Nov 09, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced a new United States investigational device exemption study to evaluate the accuracy of six-day use in...
-
Nov 8, 2011Pooled Data Analyses to Be Presented at TCT 2011 Demonstrate Heart Device's Consistently Positive Performance Across Multiple Clinical Studies
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute(R) drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT)...
-
Nov 8, 2011Final Five-Year Follow-up of Randomized ENDEAVOR IV Trial Shows Durable Safety and Efficacy of Endeavor DES, with Comparatively Lower Rates of Cardiac Death/Myocardial Infarction and Very Late Stent Thrombosis
SAN FRANCISCO, Nov 08, 2011 (BUSINESS WIRE) -- New research findings released at TCT 2011 show that the Endeavor(R) zotarolimus-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) outperformed...
-
Nov 7, 2011New Access Will Expand Treatment Options for Patients with Severe Aortic Stenosis
MINNEAPOLIS, Nov 07, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for the Medtronic CoreValve(R) System to be delivered...
-
Nov 4, 2011Presentations Cover Stents and Balloons for Coronary and Peripheral Artery Disease, Transcatheter Valve for Aortic Stenosis, Stent Grafts for Aortic Aneurysms, and Renal Denervation for Treatment-Resistant Hypertension and Heart Failure
MINNEAPOLIS, Nov 04, 2011 (BUSINESS WIRE) -- Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT)...
-
Nov 3, 2011The latest advancement in expandable cage technology for surgeons, hospitals and patients
MEMPHIS, Tenn., Nov 03, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) announced the global launch of the T2 ALTITUDE(TM) Expandable Corpectomy Device in the U.S. and Europe today at the North...
-
Nov 2, 2011
MINNEAPOLIS, Nov 02, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced the first implant in a clinical trial in Japan that will evaluate the safety and effectiveness of the...
-
Nov 2, 2011
MEMPHIS, Tenn., Nov 02, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) the world leader in spinal technology, announced today a pioneering approach to minimally invasive spinal fusion at the 26th
-
Nov 2, 2011
MINNEAPOLIS, Nov 02, 2011 (BUSINESS WIRE) -- To address surgeon needs of rapidly managing hemostasis in minimally invasive spine surgery, Medtronic, Inc. (NYSE: MDT) announced today the launch of...
-
Oct 31, 2011Assurant(R) Cobalt Iliac Stent Features Novel Alloy and Modular Design; Augments Company's Peripheral Portfolio with Balloon-Expandable Option
MINNEAPOLIS, Oct 31, 2011 (BUSINESS WIRE) -- Advancing the treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced approval by the U.S. Food and Drug Administration...
-
Oct 28, 2011
MINNEAPOLIS, Oct 28, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today The Great Place to Work Institute(R) included the company on the inaugural "World's 25 Best Multinational...
-
Oct 28, 2011A Critical Step Toward the Development of an Artificial Pancreas, Low Glucose Suspend Aims to Reduce Hypoglycemia
MINNEAPOLIS, Oct 28, 2011 (BUSINESS WIRE) -- In our continued commitment to develop an artificial pancreas, Medtronic, Inc. (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA)...
-
Oct 27, 2011
MINNEAPOLIS, Oct 27, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration's (FDA) Circulatory Systems Devices advisory panel voted against...
-
Oct 26, 2011U.S. Clinical Trial of Symplicity(R) Renal Denervation System(TM) Enrolls First Patient
MINNEAPOLIS, Oct 26, 2011 (BUSINESS WIRE) -- Medtronic Inc. (NYSE: MDT) announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity(R) Renal Denervation...
-
Oct 17, 2011
MINNEAPOLIS, Oct 17, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for its Aquamantys(R)3...
-
Oct 17, 2011
MINNEAPOLIS, Oct 17, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced that its Board of Directors unanimously voted to elect Michael O. Leavitt, founder and chairman of Leavitt...
-
Oct 13, 2011Integrity(R) Coronary Stent Redefines Deliverability with Continuous Sinusoid Technology; Endurant(R) AAA Stent Graft Expands Applicability of Endovascular Aortic Repair
MINNEAPOLIS, Oct 13, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced plans to introduce two of its next-generation cardiovascular devices in Japan, the world's second largest...
-
Oct 10, 2011First Ever Randomized, Controlled Clinical Trial in Persistent Atrial Fibrillation (AF) Patients
VENICE, Italy & MINNEAPOLIS, Oct 10, 2011 (BUSINESS WIRE) -- Medtronic, Inc.(NYSE: MDT) today announced results from its Tailored Treatment of Permanent Atrial Fibrillation (TTOP-AF) clinical...
-
Sep 27, 2011Study will evaluate new therapy option for patients suffering from valvular heart disease
MINNEAPOLIS, Sep 27, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced the start of the Engager(TM) European Pivotal Trial to pursue CE (Conformité Européenne) Mark for the...
-
Sep 20, 2011
MINNEAPOLIS, Sep 20, 2011 (BUSINESS WIRE) -- Following are statements from Herb Riband, Medtronic vice president of external affairs, and Dr. Jacob Gayle, vice president of Medtronic Foundation...
-
Sep 20, 2011
MEMPHIS, Tenn., Sep 20, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) announced today that a jury in the United States District Court of the Southern District of California in San Diego,...
-
Sep 15, 2011AIS is the Most Common Type of Scoliosis Seen in Adolescents and Affects Nearly One Million Adolescents in the U.S. Alone
MEMPHIS, Tenn., Sep 15, 2011 (BUSINESS WIRE) -- Medtronic (NYSE: MDT) announced today it received a second clearance from the Food and Drug Administration (FDA) to treat adolescent idiopathic...
-
Sep 14, 2011Medtronic Pledges Action in Advance of United Nations High Level Meeting on Noncommunicable DiseasesThe World's Leading Medical Technology Company Pledges Resources to Improve Healthcare Systems and Access to Therapies in Lower- and Middle-Income Countries
MINNEAPOLIS, Sep 14, 2011 (BUSINESS WIRE) -- In a continued mission to reduce the global burden of noncommunicable diseases (NCDs) such as cardiovascular disease and diabetes, Medtronic, Inc....
-
Sep 12, 2011New technology offers one-source, customizable option for bone grafting space maintenance in oral-maxillofacial applications
MEMPHIS, Tenn., Sep 12, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) announced today the U.S. launch of its ARTISAN(TM) Space Maintenance System. The device is cleared for temporary use in...
-
Sep 8, 2011
MINNEAPOLIS, Sep 08, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Morgan Stanley Global...
-
Sep 8, 2011Index Acknowledge Corporate Sustainability Accomplishments
MINNEAPOLIS, Sep 08, 2011 (BUSINESS WIRE) -- Recognizing its leadership in meeting the needs of economic, environmental, and social stakeholders, Medtronic, Inc. (NYSE: MDT) has been named a...
-
Aug 31, 2011Indicated for Endovascular Treatment of Abdominal Aortic Aneurysms, Medical Device Has Been Used to Treat More Than 6,000 Patients in United States Since December FDA Approval
MINNEAPOLIS, Aug 31, 2011 (BUSINESS WIRE) -- Leading the development of endovascular aortic repair (EVAR), Medtronic, Inc. (NYSE: MDT) today announced the start of its U.S. post-approval study of...